Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANA M CORREGIDOR

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1306842810
CMS profile
104311
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$33,591.84

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANA M CORREGIDOR

NPI 1306842810 · CMS profile ID 104311

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306842810?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANA M CORREGIDOR, NPI 1306842810, CMS profile ID 104311. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306842810?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANA M CORREGIDOR, NPI 1306842810, CMS profile ID 104311. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306842810?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANA M CORREGIDOR, NPI 1306842810, CMS profile ID 104311, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306842810?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $33,591.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $120.8709/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779498 CMS
Gilead Sciences, Inc. $23.7908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779496 CMS
ABBVIE INC. $23.1808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504622 CMS
ABBVIE INC. $11.8808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504624 CMS
ABBVIE INC. $3.0208/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504620 CMS
ABBVIE INC. $11.1507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504618 CMS
ABBVIE INC. $19.6107/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504616 CMS
ABBVIE INC. $13.9607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504614 CMS
ABBVIE INC. $29.5607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504612 CMS
Intercept Pharmaceuticals, Inc. $15.3007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113630458 CMS
ABBVIE INC. $9.5307/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504610 CMS
Gilead Sciences, Inc. $25.0006/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779494 CMS
Novo Nordisk Inc $2,712.5006/27/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096700184 CMS
GENZYME CORPORATION $26.8006/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139995571 CMS
ABBVIE INC. $19.1806/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504608 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153746067 CMS
Gilead Sciences, Inc. $17.5106/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779492 CMS
Lilly USA, LLC $14.2305/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136034916 CMS
ABBVIE INC. $13.0905/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504606 CMS
ABBVIE INC. $14.2105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504604 CMS
ABBVIE INC. $13.3805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504602 CMS
Lilly USA, LLC $15.2905/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136046865 CMS
ABBVIE INC. $14.0604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504600 CMS
Gilead Sciences, Inc. $17.4604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779490 CMS
ABBVIE INC. $17.3004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504598 CMS
ABBVIE INC. $23.9704/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504596 CMS
PFIZER INC. $15.7103/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131285411 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6603/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153741795 CMS
Janssen Biotech, Inc. $20.0803/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078426931 CMS
Gilead Sciences, Inc. $17.4502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779488 CMS
ABBVIE INC. $15.5202/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504594 CMS
Janssen Biotech, Inc. $25.8102/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078428582 CMS
ABBVIE INC. $23.2202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504592 CMS
ABBVIE INC. $28.2001/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504590 CMS
Gilead Sciences, Inc. $10.0901/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133779486 CMS
ABBVIE INC. $22.7201/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103504588 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,512.68 110
PY2020 $281.56 20
PY2021 $636.35 41
PY2022 $1,034.59 65
PY2023 $1,098.13 70
PY2024 $33,591.84 86
PY2025 $34,427.37 85

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $19,389.45 15
PY2024 Principal investigator $79,203.69 83
PY2023 Principal investigator $74,756.71 16
PY2022 Principal investigator $598.08 1
PY2021 Principal investigator $598.08 1
PY2020 Principal investigator $598.08 1
PY2019 Principal investigator $69,087.87 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $1,991.70 11/05/2025 Non-covered Recipient Entity
Encore Borland Groover Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307093
Principal investigator 1 Ipsen Pharma SAS $271.80 11/05/2025 Non-covered Recipient Entity
Encore Borland Groover Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307095
Principal investigator 1 Bausch Health US, LLC $30.00 09/30/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839892
Principal investigator 1 Bausch Health US, LLC $200.00 09/24/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839884
Principal investigator 1 Bausch Health US, LLC $2,403.28 07/14/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839889
Principal investigator 1 Bausch Health US, LLC $2,474.96 06/11/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839908
Principal investigator 1 Bausch Health US, LLC $361.47 06/05/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839912
Principal investigator 1 Bausch Health US, LLC $3,086.71 05/13/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839905
Principal investigator 1 Ipsen Pharma SAS $1,991.70 05/07/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184304863
Principal investigator 1 Ipsen Pharma SAS $1,538.00 04/23/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184304861
Principal investigator 1 Bausch Health US, LLC $1,357.15 04/07/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839901
Principal investigator 1 Ipsen Pharma SAS $271.80 03/05/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184304859
Principal investigator 1 Bausch Health US, LLC $1,657.88 01/28/2025 Non-covered Recipient Entity
ENCORE BORLAND GROOVER CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839896
Principal investigator 1 Ipsen Pharma SAS $1,403.00 01/24/2025 Non-covered Recipient Entity
Encore Borland Groover Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307091
Principal investigator 1 Ipsen Pharma SAS $350.00 01/14/2025 Non-covered Recipient Entity
Encore Borland Groover Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184307089